Ignite Creation Date:
2024-05-06 @ 2:33 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02072512
Status:
UNKNOWN
Last Update Posted:
2014-02-26
First Post:
2014-02-07
Brief Title:
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
Sponsor:
Hospital Affiliated to Military Medical Science Beijing
Organization:
Hospital Affiliated to Military Medical Science Beijing
Study Overview
Official Title:
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2014-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROOF
Brief Summary:
The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR advanced breast cancer
Detailed Description:
Premenopausal advanced breast cancer patients who failed tamoxifen treatment are possible good candidates for ovarian ablationsuppression and aromatase inhibitorsFulvestrant has been studied little in premenopausal women despite of its attractive mechanism of actions Based on this rationale we introduced high-dose of fulvestrant with LHRH agonist as a randomized trial comparing with AI plus LHRH agonist
To assess efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR advanced breast cancer in terms of progression-free survivalPFS
To assess efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR advanced breast cancer in terms of progression-free survivalPFS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None